3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Sarcoma
2
Mycosis Fungoides
1
Melanoma
1
Liposarcoma
1
Leiomyosarcoma
1
Hemangiosarcoma
1
Dermatofibrosarcoma
1
Carcinoma, Squamous Cell
1
Carcinoma, Merkel Cell
1
Breast Neoplasms
1
Interventions
Doxorubicin
25
Radiotherapy
16
Ifosfamide
14
Trabectedin
10
pazopanib
6
ribociclib
5
pembrolizumab
5
Specimen Handling
5
Magnetic Resonance Spectroscopy
5
Gemcitabine
5
Biopsy
5
palbociclib
4
Radiation
4
Docetaxel
4
Chemotherapy, Adjuvant
4
selinexor
3
liposomal doxorubicin
3
eribulin
3
abemaciclib
3
X-Rays
3
Vincristine
3
Neoadjuvant Therapy
3
Imatinib Mesylate
3
Filgrastim
3
Etoposide
3
Cyclophosphamide
3
toripalimab
2
temsirolimus
2
romidepsin
2
pegfilgrastim
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Liposarcoma
×
TTI-621
×
Sarcoma
×
Clear all
NCT04996004
2024-12-11
TTI-621-03
Pfizer
Phase 2
Terminated
76 enrolled
53 charts